STEVEN C GILMAN Insider Trading Transactions
Get free email notifications about insider trading for STEVEN C GILMAN.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of STEVEN C GILMAN. STEVEN C GILMAN is EVP & Chief Scientific Officer in CUBIST PHARMACEUTICALS INC ($CBST) and Senior Vice President in CUBIST PHARMACEUTICALS INC ($CBST) and SVP, Chief Scientific Officer in CUBIST PHARMACEUTICALS INC ($CBST) and in Vericel Corp ($ASTM) and Director in Vericel Corp ($ASTM) and Director in KERYX BIOPHARMACEUTICALS INC ($KERX) and Director in SCYNEXIS INC ($SCYX) and Director in MOMENTA PHARMACEUTICALS INC ($MNTA) and CEO in CONTRAFECT Corp ($CFRX) and in Akebia Therapeutics, Inc. ($AKBA) and Director in Akebia Therapeutics, Inc. ($AKBA).
Latest Insider Trading Transactions of STEVEN C GILMAN
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, AKBA, CFRX, CBST, KERX, MNTA, SCYX, ASTM
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 30 2021 | ASTM | Vericel Corp | GILMAN STEVEN C | Option Exercise | A | 63.22 | 6,500 | 410,930 | 6,500 | ||
Apr 30 2021 | ASTM | Vericel Corp | GILMAN STEVEN C | Option Exercise | A | 0.00 | 2,600 | 0 | 2,600 | ||
Apr 30 2021 | ASTM | Vericel Corp | GILMAN STEVEN C | Option Exercise | M | 0.00 | 1,750 | 0 | 0 | ||
Apr 30 2021 | ASTM | Vericel Corp | GILMAN STEVEN C | Buy | M | 0.00 | 1,750 | 0 | 3,500 | 1.8 K to 3.5 K (+100.00 %) | |
Dec 23 2020 | SCYX | SCYNEXIS INC | GILMAN STEVEN C | Director | Option Exercise | A | 8.25 | 2,000 | 16,500 | 2,000 | |
Dec 23 2020 | SCYX | SCYNEXIS INC | GILMAN STEVEN C | Director | Option Exercise | A | 7.33 | 2,000 | 14,660 | 2,000 | |
Dec 23 2020 | SCYX | SCYNEXIS INC | GILMAN STEVEN C | Director | Buy | P | 6.25 | 4,000 | 25,000 | 4,000 | 0 to 4 K |
Oct 01 2020 | MNTA | MOMENTA PHARMACEUT ... | GILMAN STEVEN C | Director | Option Exercise | D | 38.09 | 25,000 | 952,250 | 0 | |
Oct 01 2020 | MNTA | MOMENTA PHARMACEUT ... | GILMAN STEVEN C | Director | Option Exercise | D | 12.64 | 25,000 | 316,000 | 0 | |
Oct 01 2020 | MNTA | MOMENTA PHARMACEUT ... | GILMAN STEVEN C | Director | Option Exercise | D | 22.30 | 8,855 | 197,467 | 0 | |
Oct 01 2020 | MNTA | MOMENTA PHARMACEUT ... | GILMAN STEVEN C | Director | Option Exercise | D | 17.20 | 11,207 | 192,760 | 0 | |
Oct 01 2020 | MNTA | MOMENTA PHARMACEUT ... | GILMAN STEVEN C | Director | Sell | D | 0.00 | 7,796 | 0 | 0 | 7.8 K to 0 (-100.00 %) |
Aug 07 2020 | MNTA | MOMENTA PHARMACEUT ... | GILMAN STEVEN C | Director | Option Exercise | M | 10.63 | 13,000 | 138,190 | 0 | |
Aug 07 2020 | MNTA | MOMENTA PHARMACEUT ... | GILMAN STEVEN C | Director | Sell | S | 32.75 | 13,000 | 425,750 | 7,796 | 20.8 K to 7.8 K (-62.51 %) |
Aug 07 2020 | MNTA | MOMENTA PHARMACEUT ... | GILMAN STEVEN C | Director | Buy | M | 10.63 | 13,000 | 138,190 | 20,796 | 7.8 K to 20.8 K (+166.75 %) |
Jul 30 2020 | MNTA | MOMENTA PHARMACEUT ... | GILMAN STEVEN C | Director | Option Exercise | M | 10.63 | 10,000 | 106,300 | 13,000 | |
Jul 30 2020 | MNTA | MOMENTA PHARMACEUT ... | GILMAN STEVEN C | Director | Sell | S | 29.70 | 10,000 | 297,000 | 7,796 | 17.8 K to 7.8 K (-56.19 %) |
Jul 30 2020 | MNTA | MOMENTA PHARMACEUT ... | GILMAN STEVEN C | Director | Buy | M | 10.63 | 10,000 | 106,300 | 17,796 | 7.8 K to 17.8 K (+128.27 %) |
Jul 23 2020 | MNTA | MOMENTA PHARMACEUT ... | GILMAN STEVEN C | Director | Option Exercise | M | 10.63 | 10,000 | 106,300 | 23,000 | |
Jul 23 2020 | MNTA | MOMENTA PHARMACEUT ... | GILMAN STEVEN C | Director | Sell | S | 33.23 | 10,000 | 332,300 | 7,796 | 17.8 K to 7.8 K (-56.19 %) |
Jul 23 2020 | MNTA | MOMENTA PHARMACEUT ... | GILMAN STEVEN C | Director | Grant | A | 10.63 | 10,000 | 106,300 | 17,796 | 7.8 K to 17.8 K (+128.27 %) |
Jul 08 2020 | SCYX | SCYNEXIS INC | GILMAN STEVEN C | Director | Option Exercise | A | 0.73 | 45,000 | 32,850 | 45,000 | |
Jun 24 2020 | MNTA | MOMENTA PHARMACEUT ... | GILMAN STEVEN C | Director | Option Exercise | A | 38.09 | 25,000 | 952,250 | 25,000 | |
Jun 09 2020 | AKBA | Akebia Therapeutic ... | GILMAN STEVEN C | Option Exercise | A | 11.96 | 20,100 | 240,396 | 20,100 | ||
Jun 09 2020 | AKBA | Akebia Therapeutic ... | GILMAN STEVEN C | Sell | S | 12.08 | 4,567 | 55,169 | 38,864 | 43.4 K to 38.9 K (-10.52 %) | |
Jun 09 2020 | AKBA | Akebia Therapeutic ... | GILMAN STEVEN C | Grant | A | 0.00 | 13,700 | 0 | 43,431 | 29.7 K to 43.4 K (+46.08 %) | |
May 01 2020 | ASTM | Vericel Corp | GILMAN STEVEN C | Option Exercise | A | 0.00 | 1,750 | 0 | 1,750 | ||
May 01 2020 | ASTM | Vericel Corp | GILMAN STEVEN C | Option Exercise | A | 14.56 | 13,125 | 191,100 | 13,125 | ||
May 01 2020 | ASTM | Vericel Corp | GILMAN STEVEN C | Option Exercise | M | 0.00 | 1,750 | 0 | 0 | ||
May 01 2020 | ASTM | Vericel Corp | GILMAN STEVEN C | Buy | M | 0.00 | 1,750 | 0 | 1,750 | 0 to 1.8 K | |
Nov 22 2019 | AKBA | Akebia Therapeutic ... | GILMAN STEVEN C | Buy | P | 3.43 | 5,800 | 19,894 | 29,731 | 23.9 K to 29.7 K (+24.24 %) | |
Jun 21 2019 | MNTA | MOMENTA PHARMACEUT ... | GILMAN STEVEN C | Director | Option Exercise | M | 0.00 | 4,356 | 0 | 0 | |
Jun 21 2019 | MNTA | MOMENTA PHARMACEUT ... | GILMAN STEVEN C | Director | Option Exercise | A | 12.64 | 25,000 | 316,000 | 25,000 | |
Jun 21 2019 | MNTA | MOMENTA PHARMACEUT ... | GILMAN STEVEN C | Director | Buy | M | 0.00 | 4,356 | 0 | 7,796 | 3.4 K to 7.8 K (+126.63 %) |
Jun 20 2019 | SCYX | SCYNEXIS INC | GILMAN STEVEN C | Director | Option Exercise | A | 1.29 | 45,000 | 58,050 | 45,000 | |
Jun 10 2019 | AKBA | Akebia Therapeutic ... | GILMAN STEVEN C | Option Exercise | A | 4.23 | 20,100 | 85,023 | 20,100 | ||
Jun 10 2019 | AKBA | Akebia Therapeutic ... | GILMAN STEVEN C | Grant | A | 0.00 | 13,700 | 0 | 23,931 | 10.2 K to 23.9 K (+133.91 %) | |
May 03 2019 | ASTM | Vericel Corp | GILMAN STEVEN C | Option Exercise | A | 0.00 | 1,750 | 0 | 1,750 | ||
May 03 2019 | ASTM | Vericel Corp | GILMAN STEVEN C | Option Exercise | A | 16.62 | 13,125 | 218,138 | 13,125 | ||
May 03 2019 | ASTM | Vericel Corp | GILMAN STEVEN C | Option Exercise | M | 2.76 | 7,500 | 20,700 | 0 | ||
May 03 2019 | ASTM | Vericel Corp | GILMAN STEVEN C | Sell | S | 16.81 | 7,500 | 126,095 | 0 | 7.5 K to 0 (-100.00 %) | |
May 03 2019 | ASTM | Vericel Corp | GILMAN STEVEN C | Buy | M | 2.76 | 7,500 | 20,700 | 7,500 | 0 to 7.5 K | |
Mar 04 2019 | ASTM | Vericel Corp | GILMAN STEVEN C | Option Exercise | M | 2.76 | 7,500 | 20,700 | 7,500 | ||
Mar 04 2019 | ASTM | Vericel Corp | GILMAN STEVEN C | Sell | S | 18.02 | 7,500 | 135,129 | 0 | 7.5 K to 0 (-100.00 %) | |
Mar 04 2019 | ASTM | Vericel Corp | GILMAN STEVEN C | Buy | M | 2.76 | 7,500 | 20,700 | 7,500 | 0 to 7.5 K | |
Jan 04 2019 | SCYX | SCYNEXIS INC | GILMAN STEVEN C | Director | Option Exercise | A | 0.54 | 22,500 | 12,242 | 22,500 | |
Dec 13 2018 | AKBA | Akebia Therapeutic ... | GILMAN STEVEN C | Director | Option Exercise | A | 8.94 | 25,000 | 223,500 | 25,000 | |
Dec 13 2018 | AKBA | Akebia Therapeutic ... | GILMAN STEVEN C | Director | Option Exercise | A | 10.05 | 11,229 | 112,851 | 11,229 | |
Dec 13 2018 | AKBA | Akebia Therapeutic ... | GILMAN STEVEN C | Director | Option Exercise | A | 17.53 | 11,229 | 196,844 | 11,229 | |
Dec 13 2018 | AKBA | Akebia Therapeutic ... | GILMAN STEVEN C | Director | Option Exercise | A | 15.26 | 11,229 | 171,355 | 11,229 | |
Dec 13 2018 | AKBA | Akebia Therapeutic ... | GILMAN STEVEN C | Director | Option Exercise | A | 12.48 | 18,716 | 233,576 | 18,716 | |
Dec 13 2018 | AKBA | Akebia Therapeutic ... | GILMAN STEVEN C | Director | Grant | A | 0.00 | 10,231 | 0 | 10,231 | 0 to 10.2 K |
Dec 13 2018 | KERX | KERYX BIOPHARMACEU ... | GILMAN STEVEN C | Director | Option Exercise | D | 0.00 | 140,000 | 0 | 0 | |
Dec 13 2018 | KERX | KERYX BIOPHARMACEU ... | GILMAN STEVEN C | Director | Sell | D | 0.00 | 27,333 | 0 | 0 | 27.3 K to 0 (-100.00 %) |
Dec 04 2018 | ASTM | Vericel Corp | GILMAN STEVEN C | Option Exercise | M | 2.63 | 8,500 | 22,355 | 0 | ||
Dec 04 2018 | ASTM | Vericel Corp | GILMAN STEVEN C | Sell | S | 17.75 | 8,500 | 150,908 | 0 | 8.5 K to 0 (-100.00 %) | |
Dec 04 2018 | ASTM | Vericel Corp | GILMAN STEVEN C | Buy | M | 2.63 | 8,500 | 22,355 | 8,500 | 0 to 8.5 K | |
Sep 06 2018 | ASTM | Vericel Corp | GILMAN STEVEN C | Option Exercise | M | 2.63 | 9,000 | 23,670 | 8,500 | ||
Sep 06 2018 | ASTM | Vericel Corp | GILMAN STEVEN C | Sell | S | 12.03 | 9,000 | 108,270 | 0 | 9 K to 0 (-100.00 %) | |
Sep 06 2018 | ASTM | Vericel Corp | GILMAN STEVEN C | Buy | M | 2.63 | 9,000 | 23,670 | 9,000 | 0 to 9 K | |
Jul 12 2018 | KERX | KERYX BIOPHARMACEU ... | GILMAN STEVEN C | Director | Option Exercise | A | 3.76 | 30,000 | 112,800 | 30,000 | |
Jul 12 2018 | KERX | KERYX BIOPHARMACEU ... | GILMAN STEVEN C | Director | Grant | A | 0.00 | 10,000 | 0 | 27,333 | 17.3 K to 27.3 K (+57.69 %) |
Jun 26 2018 | MNTA | MOMENTA PHARMACEUT ... | GILMAN STEVEN C | Director | Sell | S | 21.50 | 2,294 | 49,321 | 3,440 | 5.7 K to 3.4 K (-40.01 %) |
Jun 22 2018 | MNTA | MOMENTA PHARMACEUT ... | GILMAN STEVEN C | Director | Option Exercise | M | 0.00 | 5,734 | 0 | 0 | |
Jun 22 2018 | MNTA | MOMENTA PHARMACEUT ... | GILMAN STEVEN C | Director | Option Exercise | A | 0.00 | 4,356 | 0 | 4,356 | |
Jun 22 2018 | MNTA | MOMENTA PHARMACEUT ... | GILMAN STEVEN C | Director | Option Exercise | A | 22.30 | 8,855 | 197,467 | 8,855 | |
Jun 22 2018 | MNTA | MOMENTA PHARMACEUT ... | GILMAN STEVEN C | Director | Buy | M | 0.00 | 5,734 | 0 | 5,734 | 0 to 5.7 K |
Jun 12 2018 | KERX | KERYX BIOPHARMACEU ... | GILMAN STEVEN C | Director | Sell | S | 5.12 | 1,334 | 6,830 | 17,333 | 18.7 K to 17.3 K (-7.15 %) |
May 31 2018 | KERX | KERYX BIOPHARMACEU ... | GILMAN STEVEN C | Director | Sell | S | 5.22 | 1,333 | 6,958 | 18,667 | 20 K to 18.7 K (-6.66 %) |
May 03 2018 | ASTM | Vericel Corp | GILMAN STEVEN C | Option Exercise | A | 13.05 | 17,500 | 228,375 | 17,500 | ||
Jan 04 2018 | SCYX | SCYNEXIS INC | GILMAN STEVEN C | Director | Option Exercise | A | 2.28 | 19,989 | 45,575 | 19,989 | |
Oct 04 2017 | SCYX | SCYNEXIS INC | GILMAN STEVEN C | Director | Option Exercise | A | 2.46 | 1,807 | 4,445 | 1,807 | |
Jul 26 2017 | CFRX | CONTRAFECT Corp | GILMAN STEVEN C | CEO | Option Exercise | P | 1.55 | 400 | 620 | 400 | |
Jul 26 2017 | CFRX | CONTRAFECT Corp | GILMAN STEVEN C | CEO | Buy | P | 1.24 | 800 | 992 | 20,800 | 20 K to 20.8 K (+4.00 %) |
Jul 05 2017 | SCYX | SCYNEXIS INC | GILMAN STEVEN C | Director | Option Exercise | A | 1.83 | 2,430 | 4,447 | 2,430 | |
Jun 22 2017 | MNTA | MOMENTA PHARMACEUT ... | GILMAN STEVEN C | Director | Option Exercise | A | 0.00 | 5,734 | 0 | 5,734 | |
Jun 22 2017 | MNTA | MOMENTA PHARMACEUT ... | GILMAN STEVEN C | Director | Option Exercise | A | 17.20 | 11,207 | 192,760 | 11,207 | |
Jun 20 2017 | KERX | KERYX BIOPHARMACEU ... | GILMAN STEVEN C | Director | Option Exercise | A | 6.56 | 30,000 | 196,800 | 30,000 | |
Jun 20 2017 | KERX | KERYX BIOPHARMACEU ... | GILMAN STEVEN C | Director | Grant | A | 0.00 | 10,000 | 0 | 20,000 | 10 K to 20 K (+100.00 %) |
Apr 04 2017 | SCYX | SCYNEXIS INC | GILMAN STEVEN C | Director | Option Exercise | A | 2.65 | 1,678 | 4,447 | 1,678 | |
Jan 05 2017 | SCYX | SCYNEXIS INC | GILMAN STEVEN C | Director | Option Exercise | A | 3.40 | 14,499 | 49,297 | 14,499 | |
Jan 05 2017 | SCYX | SCYNEXIS INC | GILMAN STEVEN C | Director | Option Exercise | A | 3.40 | 1,308 | 4,447 | 1,308 | |
Oct 04 2016 | SCYX | SCYNEXIS INC | GILMAN STEVEN C | Director | Option Exercise | A | 4.55 | 977 | 4,445 | 977 | |
Jul 27 2016 | CFRX | CONTRAFECT Corp | GILMAN STEVEN C | CEO | Option Exercise | P | 3.00 | 20,000 | 60,000 | 20,000 | |
Jul 27 2016 | CFRX | CONTRAFECT Corp | GILMAN STEVEN C | CEO | Buy | P | 2.48 | 20,000 | 49,600 | 20,000 | 0 to 20 K |
Jul 11 2016 | SCYX | SCYNEXIS INC | GILMAN STEVEN C | Director | Option Exercise | A | 2.19 | 2,030 | 4,446 | 2,030 | |
Jul 11 2016 | SCYX | SCYNEXIS INC | GILMAN STEVEN C | Director | Option Exercise | A | 2.19 | 2,030 | 4,446 | 2,030 | |
Jun 24 2016 | MNTA | MOMENTA PHARMACEUT ... | GILMAN STEVEN C | Director | Option Exercise | A | 10.63 | 33,000 | 350,790 | 33,000 | |
Jun 06 2016 | SCYX | SCYNEXIS INC | GILMAN STEVEN C | Director | Option Exercise | A | 3.98 | 8,800 | 35,024 | 8,800 | |
May 27 2016 | KERX | KERYX BIOPHARMACEU ... | GILMAN STEVEN C | Director | Option Exercise | A | 5.71 | 30,000 | 171,300 | 30,000 | |
May 27 2016 | KERX | KERYX BIOPHARMACEU ... | GILMAN STEVEN C | Director | Grant | A | 0.00 | 10,000 | 0 | 10,000 | 0 to 10 K |
May 06 2016 | ASTM | Vericel Corp | GILMAN STEVEN C | Director | Option Exercise | A | 2.76 | 15,000 | 41,400 | 15,000 | |
Apr 05 2016 | SCYX | SCYNEXIS INC | GILMAN STEVEN C | Director | Option Exercise | A | 4.05 | 1,098 | 4,447 | 1,098 | |
Jan 06 2016 | SCYX | SCYNEXIS INC | GILMAN STEVEN C | Director | Option Exercise | A | 6.10 | 729 | 4,447 | 729 | |
Oct 05 2015 | SCYX | SCYNEXIS INC | GILMAN STEVEN C | Director | Option Exercise | A | 6.64 | 670 | 4,449 | 670 | |
Jul 06 2015 | SCYX | SCYNEXIS INC | GILMAN STEVEN C | Director | Option Exercise | A | 8.86 | 502 | 4,448 | 502 | |
Jun 05 2015 | SCYX | SCYNEXIS INC | GILMAN STEVEN C | Director | Option Exercise | A | 8.65 | 8,800 | 76,120 | 8,800 | |
Apr 03 2015 | SCYX | SCYNEXIS INC | GILMAN STEVEN C | Director | Option Exercise | A | 8.76 | 554 | 4,853 | 544 | |
Mar 24 2015 | ASTM | Vericel Corp | GILMAN STEVEN C | Director | Option Exercise | A | 3.74 | 20,000 | 74,800 | 20,000 | |
Feb 27 2015 | SCYX | SCYNEXIS INC | GILMAN STEVEN C | Director | Option Exercise | A | 10.00 | 486 | 4,860 | 486 | |
Feb 27 2015 | SCYX | SCYNEXIS INC | GILMAN STEVEN C | Director | Option Exercise | A | 10.00 | 7,830 | 78,300 | 7,830 | |
Jan 21 2015 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Option Exercise | D | 0.00 | 4,046 | 0 | 0 | |
Jan 21 2015 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Option Exercise | D | 0.00 | 4,552 | 0 | 0 | |
Jan 21 2015 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Option Exercise | D | 73.55 | 31,053 | 2,283,948 | 0 | |
Jan 21 2015 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Option Exercise | D | 0.00 | 7,812 | 0 | 0 | |
Jan 21 2015 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Option Exercise | D | 0.00 | 5,859 | 0 | 0 | |
Jan 21 2015 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Option Exercise | D | 41.60 | 47,851 | 1,990,602 | 0 | |
Jan 21 2015 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Option Exercise | D | 0.00 | 7,500 | 0 | 0 | |
Jan 21 2015 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Option Exercise | D | 42.09 | 75,000 | 3,156,750 | 0 | |
Jan 21 2015 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Option Exercise | D | 34.80 | 21,875 | 761,141 | 0 | |
Jan 21 2015 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Option Exercise | D | 0.00 | 3,500 | 0 | 0 | |
Jan 21 2015 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Option Exercise | D | 25.23 | 9,375 | 236,531 | 0 | |
Jan 21 2015 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Option Exercise | D | 21.56 | 60,000 | 1,293,600 | 0 | |
Jan 21 2015 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Option Exercise | D | 16.76 | 1,000 | 16,760 | 0 | |
Jan 21 2015 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Sell | J | 102.00 | 2,851 | 290,802 | 0 | 2.9 K to 0 (-100.00 %) |
Jan 21 2015 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Sell | J | 102.00 | 27,680 | 2,823,360 | 0 | 27.7 K to 0 (-100.00 %) |
Jan 05 2015 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Buy | J | 59.96 | 82 | 4,917 | 27,680 | 27.6 K to 27.7 K (+0.30 %) |
Oct 02 2014 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Option Exercise | M | 34.80 | 48,125 | 1,674,509 | 21,875 | |
Oct 02 2014 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Sell | S | 66.50 | 400 | 26,600 | 27,598 | 28 K to 27.6 K (-1.43 %) |
Oct 02 2014 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Sell | S | 65.68 | 22,225 | 1,459,751 | 27,998 | 50.2 K to 28 K (-44.25 %) |
Oct 02 2014 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Sell | S | 65.11 | 25,500 | 1,660,359 | 50,223 | 75.7 K to 50.2 K (-33.68 %) |
Oct 02 2014 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Buy | M | 65.39 | 48,125 | 3,146,711 | 75,723 | 27.6 K to 75.7 K (+174.38 %) |
Jul 29 2014 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Option Exercise | M | 25.23 | 6,525 | 164,626 | 9,375 | |
Jul 29 2014 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Option Exercise | M | 25.23 | 34,100 | 860,343 | 15,900 | |
Jul 29 2014 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Sell | S | 62.44 | 6,525 | 407,426 | 27,598 | 34.1 K to 27.6 K (-19.12 %) |
Jul 29 2014 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Sell | S | 61.40 | 34,100 | 2,093,679 | 34,123 | 68.2 K to 34.1 K (-49.98 %) |
Jul 29 2014 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Buy | M | 25.23 | 6,525 | 164,626 | 68,223 | 61.7 K to 68.2 K (+10.58 %) |
Jul 29 2014 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Buy | M | 25.23 | 34,100 | 860,343 | 61,698 | 27.6 K to 61.7 K (+123.56 %) |
Jul 02 2014 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Buy | J | 69.82 | 107 | 7,471 | 2,851 | 2.7 K to 2.9 K (+3.90 %) |
May 15 2014 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Option Exercise | M | 16.76 | 15,125 | 253,495 | 1,000 | |
May 15 2014 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Option Exercise | M | 0.00 | 2,500 | 0 | 0 | |
May 15 2014 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Sell | S | 68.42 | 6,225 | 425,913 | 27,598 | 33.8 K to 27.6 K (-18.40 %) |
May 15 2014 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Sell | S | 67.45 | 8,900 | 600,314 | 33,823 | 42.7 K to 33.8 K (-20.83 %) |
May 15 2014 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Buy | M | 16.76 | 15,125 | 253,495 | 42,723 | 27.6 K to 42.7 K (+54.80 %) |
May 15 2014 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Sell | S | 67.50 | 1,215 | 82,013 | 27,598 | 28.8 K to 27.6 K (-4.22 %) |
May 15 2014 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Buy | M | 0.00 | 2,500 | 0 | 28,813 | 26.3 K to 28.8 K (+9.50 %) |
May 14 2014 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Option Exercise | M | 0.00 | 3,500 | 0 | 3,500 | |
May 14 2014 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Sell | S | 69.00 | 1,680 | 115,920 | 26,313 | 28 K to 26.3 K (-6.00 %) |
May 14 2014 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Buy | M | 0.00 | 3,500 | 0 | 27,993 | 24.5 K to 28 K (+14.29 %) |
Apr 02 2014 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Buy | J | 73.15 | 111 | 8,120 | 2,744 | 2.6 K to 2.7 K (+4.22 %) |
Feb 19 2014 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Option Exercise | M | 0.00 | 3,750 | 0 | 7,500 | |
Feb 19 2014 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Option Exercise | M | 0.00 | 1,953 | 0 | 5,859 | |
Feb 19 2014 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Option Exercise | A | 0.00 | 4,046 | 0 | 4,046 | |
Feb 19 2014 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Option Exercise | A | 0.00 | 4,552 | 0 | 4,552 | |
Feb 19 2014 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Option Exercise | A | 73.55 | 31,053 | 2,283,948 | 31,053 | |
Feb 19 2014 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Sell | S | 75.00 | 2,645 | 198,375 | 24,493 | 27.1 K to 24.5 K (-9.75 %) |
Feb 19 2014 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Buy | M | 0.00 | 3,750 | 0 | 27,138 | 23.4 K to 27.1 K (+16.03 %) |
Feb 19 2014 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Buy | M | 0.00 | 1,953 | 0 | 23,388 | 21.4 K to 23.4 K (+9.11 %) |
Jan 06 2014 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Gift | G | 0.00 | 190 | 0 | 21,435 | 21.6 K to 21.4 K (-0.88 %) |
Jan 06 2014 | CBST | CUBIST PHARMACEUTI ... | GILMAN STEVEN C | EVP & Chief Scienti ... | Gift | G | 0.00 | 190 | 0 | 21,625 | 21.8 K to 21.6 K (-0.87 %) |